Newly identified biomarker may help predict colon cancer progression, personalize therapy

October 15, 2015, Baylor Research Institute

Researchers at Baylor Research Institute have identified a small RNA molecule that appears to enable certain colorectal cancers to become especially aggressive, resistant to treatment and likely to migrate and invade normal tissue.

Findings suggest that detecting high levels of the molecule—SNORA42—in patient tissues could serve as a "biomarker" to help clinicians determine which patients might benefit from more aggressive therapy against the disease that is the second-leading cause of cancer-related deaths in the U.S.

This is the first RNA molecule of its kind to be identified as a biomarker for . Because this type is more stable than other RNA molecules, the researchers believe noninvasive blood or stool tests eventually may be developed to quickly and easily detect SNORA42 and others that may be discovered in the future.

"We need predictive biomarkers that can identify patients who are at high risk for developing tumor recurrence, especially in those with stage 2 colorectal cancer," said Ajay Goel, PhD, director of the Center for Gastrointestinal Cancer Research and for Epigenetics and Cancer Prevention at Baylor Research Institute.

In stage 2 of the disease, the cancer has grown to some extent but has not spread to lymph nodes or distant organs. At this stage, doctors and patients often face a difficult decision: treat with surgery alone, or follow surgery with chemotherapy and its potential side effects?

"The majority of patients with stage 2 colorectal cancer will be cured with surgery alone, but some will relapse and eventually die. Molecular biomarkers, such as SNORA42, could help determine which patients might have a better prognosis with more aggressive treatment. They also provide us with targets for the development of very specific, personalized anti-cancer interventions," said Goel, the study's lead investigator and senior author of an article in the Oct. 15, 2015, journal Gut.

Goel and his colleagues studied levels of SNORA42 in six established colorectal cancer cell lines and in 250 samples of cancer tissue taken from patients, comparing these with 24 matched specimens from normal tissue.

According to their results:

  • SNORA42 was "overexpressed" in colorectal cancer cells, compared with normal tissue, and its expression significantly correlated with disease progression.
  • Overexpression resulted in cancer cells' ability to multiply rapidly, form tumors, migrate, invade normal tissue and survive a natural cell death process.
  • When SNORA42 was experimentally suppressed, these effects were reversed.
  • Elevated expression appeared to be a predictor for recurrence and poor prognosis in with colorectal cancer.

Goel said these experimental findings about SNORA42, if confirmed in additional studies, may become useful in clinical settings within several years. He also expects other molecular biomarkers will be discovered, giving researchers and clinicians new potential therapeutic targets, helping to predict patient prognosis and guiding treatment decisions.

Small RNA molecules, called microRNAs, were discovered about 15 years ago and provided a new area of exploration for cancer researchers. Goel's laboratory has identified several microRNAs that can be used as biomarkers for colorectal cancer. SNORAs—small nucleolar RNAs—are a subset of microRNAs that are only now being recognized for their role in cell fate and the development of various cancers.

SNORA42 is the first SNORA to be identified as a biomarker for colorectal , said Goel, who recently described his group's research at two international scientific conferences. He added that SNORAs are less vulnerable than other microRNAs to biodegradation in a clinical lab setting. Their strength and stability allow them to be studied more extensively, possibly leading to noninvasive blood or stool tests to quickly and easily detect them.

Explore further: Poor survival among colorectal cancer patients tied to biomarker CSN6

More information: Gut: "Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer." Oct. 15, 2015. DOI: 10.1135/gutjnl-2015-309359

Related Stories

Poor survival among colorectal cancer patients tied to biomarker CSN6

August 10, 2015
A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.

Most cancer patients believe surgery will be curative

October 8, 2015
(HealthDay)—Most patients undergoing surgery for lung or colorectal cancer believe that the surgery is likely to be curative, according to a study published in the Oct. 15 issue of Cancer.

New drug targets the source of cancer renewal

September 25, 2015
A new class of drug that reduces cancer recurrence and spread may soon be available, with South Australian biopharmaceutical company Bionomics having passed review by the US Food and Drug Administration (FDA) with their product ...

New epigenetic study reveals exciting insights into colorectal cancer progression

September 11, 2015
Researchers at Nanjing University, China, found new epigenetic markers for colorectal cancer which may offer a new approach for treatment.

Researchers use gut bacteria composition to genetically classify colorectal tumors

October 9, 2015
By analyzing the types of gut bacteria present around colorectal tumors, researchers have found a way to predict key genetic mutations in the tumors themselves, a method that could eventually inform the development of colorectal ...

Biomarker discovery offers clearer prognosis for bowel and rectal cancer patients

February 19, 2015
For the first time, a biomarker discovered by Macquarie University and Concord Repatriation General Hospital researchers will allow clinicians to distinguish certain types of colorectal cancer patients who do relatively well ...

Recommended for you

3-D mammography detected 34% more breast cancers in screening

October 15, 2018
In traditional mammography screening, all breast tissue is captured in a single image. Breast tomosynthesis, on the other hand, is three-dimensional and works according to the same principle as what is known as tomography. ...

More clues revealed in link between normal breast changes and invasive breast cancer

October 15, 2018
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process—changes in mammary glands to accommodate breastfeeding—uses a molecular process believed ...

Cancer stem cells use 'normal' genes in abnormal ways

October 12, 2018
CDK1 is a "normal" protein—its presence drives cells through the cycle of replication. And MHC Class I molecules are "normal" as well—they present bits of proteins on the surfaces of cells for examination by the immune ...

Obesity linked to increased risk of early-onset colorectal cancer

October 12, 2018
Women who are overweight or obese have up to twice the risk of developing colorectal cancer before age 50 as women who have what is considered a normal body mass index (BMI), according to new research led by Washington University ...

Potential therapy for treatment-resistant hypothyroidism proves effective in lab study

October 12, 2018
A new "metal-coordinated" drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to ...

Researchers find a 'critical need' for whole genome sequencing of young cancer patients

October 12, 2018
St. Jude Children's Research Hospital has re-defined the gold standard for diagnostic testing of childhood cancer patients in the precision-medicine era and has implemented the testing for new cancer patients. The findings ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.